MAbLaunch is a joint bioproduction platform combining LFB Group and Sanofi capabilities in the field of contract development and manufacturing services. The platform is supported by a collaboration agreement between the LFB Group and Sanofi to capitalize on the use of their respective industrial capacities and to provide the widest...
Read more
Blog
Karin Mayer Rubinstein New IATI CEO
Karin Mayer Rubinstein has been named as CEO of the Israel Advanced Technology Industries (IATI), the result of the merger between the High Tech Industry Association (HTIA) and Israel Life Science Industry (ILSI) that was officially announced on Jan. 17. The IATI aims to be the umbrella organization of the...
Read more
New Teva CEO Boosts Share Price
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has appointed Dr. Jeremy Levin as Teva’s new president and CEO. Levin joins Teva after serving as business development manager at Bristol-Myers Squibb (NYSE:BMY) and Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ). Earlier, he was CEO of Better get directions. Which no...
Read more
InsuLine Type 1 Diabetes Trial Success
InsuLine Medical Ltd. (TASE: INSL) announced positive results in efficacy and safety in a clinical trial of its insulin patch, InsuPatch for the treatment of Type 1 (juvenile) diabetes. The InsuPatch met its primary endpoint for obtaining US Food and Drug Administration (FDA) approval of the product. The InsuPatch achieved...
Read more
Baize Invests $8 M in Compugen’s mAbs
Compugen Ltd. (NASDAQ: CGEN) is accelerating its monoclonal antibody (mAb) activities for oncology and immunology after receiving a $8 million investment from Baize Investments. The expanded activities will include a significant increase in the number of mAb candidates being developed in parallel against Compugen-discovered targets and the planned in-house establishment...
Read more